Dymicron’s Triadyme-C artificial disc earned the FDA’s investigational device exemption approval, according to a July 10 news release.
The IDE approval opens the door for a U.S. trial of the disc, which is designed for patients with degenerative disc disease. Triadyme-C has bearing surfaces made of Adymite, a proprietary medical grade polycrystalline diamond material made for high-stress load-bearing environments.
“The Triadyme-C represents a remarkable advancement in cervical disc technology,” Richard Guyer, MD, co-primary investigator for clinical trials, said in the release. “Its revolutionary polycrystalline diamond bearing surfaces dramatically reduce wear debris generation, while the tri-lobed design is engineered to closely replicate normal spinal kinematics—two factors that could improve long-term outcomes for patients.”
The first implantations in the U.S. are expected in the fourth quarter.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
